BioCatalystWatch
REGNWorkspace / REGN / OverviewCompany library
REGENERON PHARMACEUTICALS, INC. logo

REGENERON PHARMACEUTICALS, INC.

REGENERON PHARMACEUTICALS, INC. (REGN)

Website

Price
Market cap
Next catalyst4Q 2026cemdisiran + pozelimab · Phase 3 dataSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

Lynozyfic (linvoseltamab-gcpt)

BCMA × CD3

PreINDP1P2P3FilingApproved
Cemdisiran

C5

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

NPR1

PreINDP1P2FilingApproved
Upcoming / outlook

LAG-3

PreINDP1P2P3FilingApproved
Upcoming / outlook

VEGF-A × PlGF

PreINDP1P2P3FilingApproved
Upcoming / outlook

fianlimab + cemiplimab

LAG-3 / PD-1

PreINDP1P2P3FilingApproved
Upcoming / outlook

cemdisiran + pozelimab

C5

PreINDP1P2P3FilingApproved
Upcoming / outlook

fianlimab + cemiplimab

LAG-3 / PD-1

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

fianlimab + cemiplimab

LAG-3 / PD-1

PreINDP1P2P3FilingApproved
Upcoming / outlook

fianlimab + cemiplimab

LAG-3 / PD-1

PreINDP1P2P3FilingApproved
Upcoming / outlook

cemdisiran + pozelimab

C5

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

mibavademab

LEPR

PreINDP1P2P3FilingApproved
mibavademab

LEPR

PreINDP1P2P3FilingApproved
mibavademab

LEPR

PreINDP1P2P3FilingApproved

Zaire ebolavirus glycoprotein

Cenvacibart

Factor XI (catalytic domain)

PreINDP1P2P3FilingApproved
Amrecibart

Factor XI (A2 domain)

PreINDP1P2P3FilingApproved
Cenvacibart

Factor XI (catalytic domain)

Amrecibart

Factor XI (A2 domain)

PreINDP1P2P3FilingApproved

Partner / License out

IL-4Rα

Upcoming / outlook

IL-4 × IL-13

Upcoming / outlook

TTR

PreINDP1P2P3FilingApproved

ANGPTL3

Approved

PreINDP1P2P3FilingApproved

Approved / commercial

PD-1

Approved

PreINDP1P2P3FilingApproved

PD-1

Approved

PreINDP1P2P3FilingApproved

PD-1

Approved

PreINDP1P2P3FilingApproved

VEGF-A × PlGF

Approved

PreINDP1P2P3FilingApproved

VEGF-A × PlGF

Approved

PreINDP1P2P3FilingApproved

VEGF-A × PlGF

Approved

PreINDP1P2P3FilingApproved

Activin A

PreINDP1P2P3FilingApproved
Upcoming / outlook

History / paused

Cenvacibart

Factor XI (catalytic domain)

PreINDP1P2P3FilingApproved
Amrecibart

Factor XI (A2 domain)

PreINDP1P2P3FilingApproved

NPR1

PreINDP1P2P3FilingApproved

Bet v 1

PreINDP1P2P3FilingApproved
Itepekimab

IL-33

PreINDP1P2P3FilingApproved
Itepekimab

IL-33

PreINDP1P2P3FilingApproved

Activin A

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Operating
Investing
Financing

Reported shares and borrowings

Shares outstanding

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

REGN PR & News

PR & News

REGN SEC archive